Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadoxetate disodium
Drug ID BADD_D00995
Description Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. It is marketed by Bayer HealthCare Pharmaceuticals and FDA approved on July 3, 2008.
Indications and Usage Gadoxetate is used as a contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions in the liver.
Marketing Status approved
ATC Code V08CA10
DrugBank ID DB08884
KEGG ID D04288
MeSH ID C073590
PubChem ID 9961939
TTD Drug ID D0X2FT
NDC Product Code 61662-0020; 50419-320
UNII HOY74VZE0M
Synonyms gadolinium ethoxybenzyl DTPA | Gd-EOB-DTPA | gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid | gadoxetic acid | gadoxetic acid disodium | gadoxetate disodium | disodium gadoxetate | gadolinium (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanoic acid disodium salt | Eovist | Primovist
Chemical Information
Molecular Formula C23H28GdN3Na2O11
CAS Registry Number 135326-22-6
SMILES CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O -].[Na+].[Na+].[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Back pain15.03.04.005--
Blood pressure increased13.14.03.005--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.016--
Conjunctivitis11.01.06.012; 06.04.01.002--
Cough22.02.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Nausea07.01.07.001--
Pallor08.01.03.032; 24.03.04.001; 23.03.03.031--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pharyngeal oedema22.04.05.003; 10.01.05.016; 23.04.01.016--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Respiratory disorder22.02.07.002--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Rhinitis22.07.03.006; 11.01.13.004--
Shock24.06.02.002--Not Available
Sneezing22.12.03.024--
The 1th Page    1 2    Next   Last    Total 2 Pages